Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADG116 First-in-Human Study in Advanced Solid Tumors
NCT04111445Phase 1Terminated
- Sponsor
- Adagene
- Start
- Aug 2019
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adg116 in solid tumor (advanced stage), sponsored by Adagene. Primary endpoints: Dose-Limiting Toxicities and Adverse Events. Started Aug 2019; status: terminated.
02
Drugs
adg116
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04111445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111445.